<br />
RHEUMATOLOGY<br />
EMJ Rheumatol. 2017 Suppl 13 • europeanmedical-journal.com<br />
INSIDE<br />
Considering Patients’ Needs: Action and<br />
Reaction of Interleukin-6 Blockade<br />
Interleukin-23: The Common<br />
Link Between the Joint,<br />
the Gut, and the Skin?<br />
CONSIDERING PATIENTS’ NEEDS: ACTION AND<br />
REACTION OF INTERLEUKIN-6 BLOCKADE<br />
This symposium took place on 14th June 2017, as a part<br />
of the European League Against Rheumatism (EULAR)<br />
18th Annual European Congress in Madrid, Spain<br />
Chairperson<br />
Costantino Pitzalis1<br />
Speakers<br />
Josef S. Smolen,2 Ernest Choy3<br />
1. Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and<br />
the London School of Medicine and Dentistry, Queen Mary University of London, London, UK<br />
2. Division of Rheumatology, Department of Medicine, Medical Un<a title="EMJ Rheumatol. 2017 Suppl 13 page 1" href="http://viewer.zmags.com/publication/110921a6?page=1"> RHEUMATOLOGY EMJ Rheumatol. 2017 Suppl 13 • europ</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 2" href="http://viewer.zmags.com/publication/110921a6?page=2"> CONSIDERING PATIENTS’ NEEDS: ACTION AND REACT</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 3" href="http://viewer.zmags.com/publication/110921a6?page=3"> Welcome and Introduction Professor Costantino P</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 4" href="http://viewer.zmags.com/publication/110921a6?page=4"> Rheumatoid joint </a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 5" href="http://viewer.zmags.com/publication/110921a6?page=5"> treatment and stronger medication (e.g. anti-TNF-</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 6" href="http://viewer.zmags.com/publication/110921a6?page=6"> IL-6 sIL-6R mIL-6R gp130 JAK1 JAK2 </a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 7" href="http://viewer.zmags.com/publication/110921a6?page=7"> The SIRROUND-D trial consisted of 104 weeks of th</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 8" href="http://viewer.zmags.com/publication/110921a6?page=8"> personal, or socio-environmental factors. Another</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 9" href="http://viewer.zmags.com/publication/110921a6?page=9"> destruction in moderate to severe rheumat</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 10" href="http://viewer.zmags.com/publication/110921a6?page=10"> INTERLEUKIN-23: THE COMMON LINK BETWEEN </a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 11" href="http://viewer.zmags.com/publication/110921a6?page=11"> rheumatologist. For example, in a randomised</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 12" href="http://viewer.zmags.com/publication/110921a6?page=12"> A study from the Psoriasis Longitudinal Assessmen</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 13" href="http://viewer.zmags.com/publication/110921a6?page=13"> linked to both psoriasis and PsA10 and pla</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 14" href="http://viewer.zmags.com/publication/110921a6?page=14"> UST: 45 mg UST: 90 mg Patients achievi</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 15" href="http://viewer.zmags.com/publication/110921a6?page=15"> active bowel inflammation but no evidence of</a>
<a title="EMJ Rheumatol. 2017 Suppl 13 page 16" href="http://viewer.zmags.com/publication/110921a6?page=16"> 5. Wendler J et al. Ustekinumab for the tr</a>